New antibody combo takes on tough pancreatic cancer
NCT ID NCT05632328
First seen Apr 17, 2026 · Last updated Apr 30, 2026 · Updated 1 time
Summary
This study tests a new drug combination (AGEN1423 and botensilimab) with or without chemotherapy in people with advanced pancreatic cancer that has worsened after at least one prior treatment. The goal is to see if the combination can shrink tumors or slow the disease. About 24 adults will receive treatment for up to 2 years, followed by 1 year of monitoring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.